The positive forecast of ‘Sivextro’ expecting sales worth of $900 billion before 2019
‘
Sivextro (generic name: tedizolid)’, a super antibiotic developed by Dong-A ST, is positively forecasted to make the highest sales, including sales in the U.S. and Europe, worth of at least $600 to $900 million in 2019.
KDB Daewoo Securities Co. made the forecast above through the latest analyt...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
